Anti-thrombotic therapy in infective endocarditis
- PMID: 21932963
- DOI: 10.1586/erc.11.100
Anti-thrombotic therapy in infective endocarditis
Abstract
Despite advances in medical and surgical treatment, infective endocarditis (IE) still carries a high risk of morbidity and mortality. One of the determinants of an adverse outcome is the presence of systemic embolization and in particular, of CNS embolization. IE vegetations consist of bacteria, platelets and inflammatory cells in a fibrin mesh. The interactions between pathogens, platelets and the coagulation system are critical to vegetation initiation and growth. This understanding has led to the study of the effect of anti-thrombotic treatment on IE vegetation formation and embolization. Although it has been demonstrated that antiplatelet and anticoagulant strategies have an impact on in vitro and animal models of IE, results from the available clinical studies are conflicting. In this article, we provide an overview of the available experimental and clinical data on anti-thrombotic treatment in IE and summarize the current guidelines. An early diagnosis, prompt empiric antibiotic treatment and a careful selection of patients who benefit from early surgical intervention remain essential in the prevention of embolic complications. In patients who have other indications for antiplatelet or anticoagulant treatment, the continuation of this treatment is deemed safe in the absence of hemorrhagic complications.
Similar articles
-
Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis.Clin Infect Dis. 2007 May 1;44(9):1180-6. doi: 10.1086/513197. Epub 2007 Mar 14. Clin Infect Dis. 2007. PMID: 17407036
-
Infective endocarditis: diagnosis and management.Nat Clin Pract Cardiovasc Med. 2006 Jun;3(6):310-7. doi: 10.1038/ncpcardio0535. Nat Clin Pract Cardiovasc Med. 2006. PMID: 16729009 Review.
-
Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis.Clin Infect Dis. 2001 Jul 15;33(2):203-9. doi: 10.1086/321814. Epub 2001 Jun 20. Clin Infect Dis. 2001. PMID: 11418880 Review.
-
Prophylaxis of experimental endocarditis with antiplatelet and antithrombin agents: a role for long-term prevention of infective endocarditis in humans?J Infect Dis. 2015 Jan 1;211(1):72-9. doi: 10.1093/infdis/jiu426. Epub 2014 Aug 1. J Infect Dis. 2015. PMID: 25086177
-
Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study.Circulation. 2005 Jul 5;112(1):69-75. doi: 10.1161/CIRCULATIONAHA.104.493155. Epub 2005 Jun 27. Circulation. 2005. PMID: 15983252
Cited by
-
In Vitro and In Vivo Model to Study Bacterial Adhesion to the Vessel Wall Under Flow Conditions.J Vis Exp. 2015 Jun 11;(100):e52862. doi: 10.3791/52862. J Vis Exp. 2015. PMID: 26131651 Free PMC article.
-
Antithrombotic Therapy in Patients With Infective Endocarditis: A Systematic Review and Meta-Analysis.JACC Adv. 2023 Dec 19;3(2):100768. doi: 10.1016/j.jacadv.2023.100768. eCollection 2024 Feb. JACC Adv. 2023. PMID: 38939390 Free PMC article.
-
Bacterial interactions with platelets: defining key themes.Front Immunol. 2025 Jul 3;16:1610289. doi: 10.3389/fimmu.2025.1610289. eCollection 2025. Front Immunol. 2025. PMID: 40677721 Free PMC article. Review.
-
Complex case of COVID-19 and infective endocarditis.BMJ Case Rep. 2021 Aug 3;14(8):e242205. doi: 10.1136/bcr-2021-242205. BMJ Case Rep. 2021. PMID: 34344645 Free PMC article.
-
Coagulation and infective endocarditis: sooner or later.Intern Emerg Med. 2015 Aug;10(5):539-41. doi: 10.1007/s11739-015-1258-9. Epub 2015 Jun 2. Intern Emerg Med. 2015. PMID: 26033535 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources